SLC5A2 and type 2 diabetes mellitus: However, the use of SGLT-2 inhibitors, including Sotagliflozin, Empagliflozin, and Canagliflozin, was not found to be associated with the incidence of skin cancer in patients with T2D in a meta-analysis (18).